Specifications
- Antibody type:Primary
- Antigen name:PARK9/ATP13A2
- Clonality:Polyclonal
- Conjugation:Alexa Fluor® 680
- Host:Rabbit
- ImmunoChemistry:Yes
- ImmunoFluorescence:Yes
- Isotype:IgG
- Reactivity:Rat
- Epitope:1001-1080/1180
- Form:Liquid
- Antigen synonyms:HSA9947|AT132_HUMAN|CLN12|PARK9|RP1-37C10.4|ATPase type 13A2|Putative ATPase|KRPPD|Probable cation-transporting ATPase 13A2|Atp13a2|Probable cation transporting ATPase 13A2
- Modification:Unmodified
- Storage buffer:Aqueous buffered solution containing 0,01 M TBS (pH 7,4) with 1% BSA, 0,03% Proclin300 and 50% Glycerol
- Molecular weight:129 kDa
- Storage temperature:Store at −20 °C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
- Concentration:1 µg/µl
- Shipping temperature:4 °C
- Immunogen:KLH conjugated synthetic peptide derived from human ATP13A2
- Tested applications:ICC
- Purification:Purified by Protein A
- Pack type:Vial
- Pk:100 µl
Specifications
About this item
ATP13A2 is a 1180 amino acid multi-pass membrane protein that belongs to the P5 subfamily of ATPases which play an important role in the transportation of inorganic cations. Expressed as multiple alternative spliced isoforms, ATP13A2 functions to catalyse the conversion of ATP to ADP and a free phosphate, thereby participating in the active transport of ions across cellular membranes. Defects in the gene encoding ATP13A2 are the cause of Kufor-Rakeb syndrome (KRS), a rare hereditary type of Parkinson's disease that exhibits juvenile onset and is characterised by neurodegeneration and dementia. The ATP13A2 gene maps to human chromosome 1, which spans 260 million base pairs, contains over 3000 genes and comprises nearly 8% of the human genome.
Type: Primary
Antigen: PARK9/ATP13A2
Clonality: Polyclonal
Clone:
Conjugation: ALEXA FLUOR® 680
Public Immunogen Range: 1001-1080/1180
Host: Rabbit
Isotype: IgG
Reactivity: Rat